The clinical research on catheter constant drainage combined with pericardial perfusion lentinan for malignant pericardial effusion caused by lung cancer
10.3760/cma.j.issn.1673-4904.2013.06.001
- VernacularTitle:导管持续引流心包积液联合香菇多糖心包腔内灌注治疗肺癌导致恶性心包积液临床研究
- Author:
Xuebin JIANG
;
Fanghua SONG
;
Danni SHAN
;
Xiaoqin YIN
- Publication Type:Journal Article
- Keywords:
Pericardium;
Drainage;
Pericardial effusion;
Lentinan
- From:
Chinese Journal of Postgraduates of Medicine
2013;(6):1-3
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effect and safety of catheter constant drainage combined with pericardial perfusion lentinan in treatment of patients with malignant pericardial effusion caused by lung cancer.Methods One hundred and eighteen patients with malignant pericardial effusion caused by lung cancer were divided into 2 groups by table of random digit,the treatment group (56 cases) was treated by pericardial perfusion lentinan after catheter constant drainage by central venous catheter,and the control group (62 cases) was treated by pericardial perfusion cisplatin after catheter constant drainage by central venous catheter.The therapeutic effect and adverse reaction were contrasted between the two groups.Results There was no significant difference in effective rate between treatment group and control group [89.3％(50/56) vs.83.9％ (52/62),x2 =0.736,P =0.391].The adverse reaction rate of treatment group was significantly lower than that of control group [8.9％ (5/56) vs.24.2％ (15/62),x2 =4.871,P =0.027].There was no significant difference in recurrence rate between treatment group and control group [14.3％(8/56) vs.11.3％(7/62),x2 =0.004,P =0.948].Conclusions Catheter constant drainage combined with pericardial perfusion lentinan for malignant pericardial effusion caused by lung cancer is safety and effective,and can be widely applied to clinical application.
